» Articles » PMID: 15795641

Influence of Cyclosporine on the Serum Concentration and Biliary Excretion of Mycophenolic Acid and 7-O-mycophenolic Acid Glucuronide

Overview
Journal Ther Drug Monit
Specialty Pharmacology
Date 2005 Mar 30
PMID 15795641
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The authors have investigated whether cyclosporine decreases the serum concentration of mycophenolic acid, the active principle of the immunosuppressant mycophenolate mofetil, and increases that of the inactive metabolite 7-O-mycophenolic acid glucuronide by reducing their enterohepatic recirculation. Rats were treated daily with methylcellulose (1.66 mL/kg PO) plus 0.9% NaCl (6 mL/kg IP), mycophenolate mofetil (20 mg/kg PO) plus 0.9% NaCl (6 mL/kg IP), methylcellulose (1.66 mL/kg PO) plus cyclosporine (5 mg/kg IP), and mycophenolate mofetil (20 mg/kg PO) plus cyclosporine (5 mg/kg IP). After 14 days a bile fistula was installed to measure the biliary excretion of the immunosuppressants and their metabolites. After 90 minutes blood was taken to determine their concentrations in blood or serum by HPLC. Cyclosporine significantly decreased the serum concentration of mycophenolic acid by 39% and increased, not significantly, that of 7-O-mycophenolic acid glucuronide by 53%. The biliary excretion of 7-O-mycophenolic acid glucuronide was significantly reduced by cyclosporine by 57%, whereas that of mycophenolic acid was not affected. Mycophenolate mofetil did not show a significant effect on either the blood concentration or the biliary excretion of cyclosporine and its metabolites AM1, AM9, AM1c, and AM4N. Cyclosporine significantly decreased the serum concentration of active mycophenolate acid and increased, not significantly, the serum concentration of inactive 7-O-mycophenolic acid glucuronide, presumably by reducing the biliary excretion of this inactive metabolite.

Citing Articles

Association of ABCC2 Haplotypes to Mycophenolic Acid Pharmacokinetics in Stable Kidney Transplant Recipients.

Brazeau D, Meaney C, Consiglio J, Wilding G, Cooper L, Venuto R J Clin Pharmacol. 2021; 61(12):1592-1605.

PMID: 34169529 PMC: 9358627. DOI: 10.1002/jcph.1932.


Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients.

Xiang H, Zhou H, Zhang J, Sun Y, Wang Y, Han Y Front Pharmacol. 2021; 12:652333.

PMID: 33912061 PMC: 8072337. DOI: 10.3389/fphar.2021.652333.


Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant.

Meaney C, Sudchada P, Consiglio J, Wilding G, Cooper L, Venuto R J Clin Pharmacol. 2019; 59(10):1351-1365.

PMID: 31062373 PMC: 7375007. DOI: 10.1002/jcph.1428.


Comparison of PETINIA and LC-MS/MS for determining plasma mycophenolic acid concentrations in Japanese lung transplant recipients.

Kikuchi M, Tanaka M, Takasaki S, Takahashi A, Akiba M, Matsuda Y J Pharm Health Care Sci. 2018; 4:7.

PMID: 29619240 PMC: 5879875. DOI: 10.1186/s40780-018-0101-7.


Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients.

Mazidi T, Rouini M, Ghahremani M, Dashti-Khavidaki S, Lessan-Pezeshki M, Ahmadi F Iran J Pharm Res. 2013; 12(3):547-56.

PMID: 24250661 PMC: 3813283.